Enzolytics Inc. Reports Continued Zero Sales and Increased Net Loss of $92,239 for Q1 2025, EPS Unchanged at $(0.00)
Enzolytics Inc. reported zero sales and a net loss of $92,239 for Q1 2025, with EPS unchanged at $(0.00). The loss improved from $172,757 in Q1 2024, while expenses decreased to $82,983 from $172,721. Cash and cash equivalents fell to $0 from $14,682 at the end of 2024. The company continues to operate without sales, focusing on expense management, and did not provide future guidance.
Enzolytics Inc. has announced its financial results for the three months ended March 31, 2025. The company reported no sales or revenues for the period, consistent with the same quarter in the previous year. The net loss for the quarter was $92,239, a slight improvement from the $172,757 loss reported in the same period in 2024. Expenses for the quarter totaled $82,983, down from $172,721 in the prior year, with significant reductions in consulting and professional fees. The company's cash and cash equivalents were reported at $0 as of March 31, 2025, compared to $14,682 at the end of 2024. Enzolytics continues to operate without generating sales, focusing on managing its expenses and liabilities. The company did not provide forward-looking guidance or forecasts in this release.
